Met
Met, the hepatocyte growth factor receptor, is a receptor tyrosine kinase that integrates growth, survival, migration, and tissue-remodelling cues during morphogenesis, wound repair, organ homeostasis, and cancer metastasis[1]. Mechanistically, HGF binding activates c-Met and downstream signaling programs linked to proliferation, motility, invasion, and survival[2]. In disease models, aberrant MET activation supports tumor growth and metastatic progression, making HGF/MET signaling a practical axis for cancer biology and drug-response studies[3]. Compared with the related HGF isoform NK1, full-length HGF activates c-Met through an asymmetric complex, whereas NK1 forms a symmetric c-Met signaling complex[4]. For experimental applications, MET inhibitors and HGF/MET-blocking agents provide tools to test kinase-dependent signaling, invasion, and therapeutic vulnerability in MET-driven models[5].
References:
- [1]. Trusolino L, et al. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48. [Content Brief]
- [2]. Birchmeier C, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25. [Content Brief]
- [3]. Gherardi E, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012 Jan 24;12(2):89-103. [Content Brief]
- [4]. Uchikawa E, et al. Structural basis of the activation of c-MET receptor. Nat Commun. 2021 Jul 1;12(1):4074. [Content Brief]
- [5]. Comoglio PM, et al. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008 Jun;7(6):504-16. [Content Brief]
-
Met Related Products (45)
Related Products (45)
-
Antibodies (3)
-
PARP1/c-Met-IN-2
0 ImagesCat. No.: HY-178348PARP1/c-Met-IN-2 is a highly potent, orally active, PARP1 (IC50 = 21.8 nM) and c-Met (IC50 = 30.2 nM) dual inhibitor. PARP1/c-Met-IN-2 can elevate the expression level of γH2AX, cause DNA damage. PARP1/c-Met-IN-2 exhibits remarkable anti-tumor efficacy in the Olaparib (HY-10162)-resistant HCT116 (HCT116OR) xenograft models. PARP1/c-Met-IN-2 can be used for the study of Colon Cancer.
-
c-Met ligand-1
0 ImagesCat. No.: HY-W425461CAS No.: 1103506-79-1
-
PF-04217903 phosphate
0 ImagesCat. No.: HY-12017CCAS No.: 1159490-83-1PF-04217903 phosphate is an orally active, highly selective ATP-competitive c-Met kinase inhibitor with a Ki value of 4.8 nM and a Kd value of 4.5 nM. PF-04217903 phosphate blocks c-Met and HGF signaling pathways, inhibits MET phosphorylation, and blocks downstream MAPK, PI3K/AKT and PLCγ1 pathways. PF-04217903 phosphate suppresses tumor proliferation, survival, migration, invasion, angiogenesis and metastasis, induces apoptosis, and enhances efferocytosis, Annexin A1 expression and resolution of inflammation. PF-04217903 phosphate retains activity against several c-Met mutants (M1131T, V1220I, H1094R). PF-04217903 phosphate increases the incidence of subarachnoid hemorrhage and reduces survival rate without altering aneurysm formation, and also prevents lymph node metastasis induced by VEGF inhibition. PF-04217903 phosphate is applicable to research related to tumors (pancreas, stomach, lung, brain, colon, breast, kidney, melanoma, etc.), intracranial aneurysms and inflammatory diseases (gouty arthritis, neutrophilic pleuritis).
-
STA-1474 sodium
0 ImagesCat. No.: HY-13752BCAS No.: 1402907-09-8STA-1474 sodium is an orally active and highly selective HSP90 inhibitor, as well as a phosphate prodrug of the HSP90 inhibitor STA-9090 (HY-15205). STA-1474 sodium disrupts the chaperone function of HSP90 and promotes the degradation of client proteins. STA-1474 sodium inhibits the phosphorylation of Met, Akt and STAT3, thereby blocking related signaling pathways. STA-1474 sodium induces apoptosis and inhibits proliferation of osteosarcoma cells, and triggers the up-regulation of HSP70 and HSP90. STA-1474 sodium induces tumor regression and caspase-3 activation in mouse osteosarcoma xenograft models. STA-1474 sodium can be used in the research of osteosarcoma.
-
1D-2
0 ImagesCat. No.: HY-114572CAS No.: 1635405-90-11D-2 is a c-Met protein kinase inhibitor, with a human-derived IC50 of 1.45 nM. 1D-2 inhibits the proliferation of cancer cells and exhibits metabolic stability in human and rat liver microsomes. 1D-2 can be used in related research on non-small cell lung cancer.
